Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

  • STATUS
    Recruiting
  • participants needed
    200
  • sponsor
    Fudan University
Send
Updated on 19 February 2024
See if I qualify

Summary

To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.

Details
Condition NSCLC Patients
Age 18-100 years
Treatment pabolizumab, nafulizumab
Clinical Study IdentifierNCT04427475
SponsorFudan University
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Sign informed consent
The age is greater than or equal to 18 years old
There is at least one measurable focus according to the RECIST 1.1 standard
EGFR / ALK detection is not needed in patients with metastatic (stage IV) EGFR / ALK wild-type NSCLC confirmed by histology or cytology and in patients with squamous cell carcinoma
Cohort 1: patients receiving anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment Cohort 2: patients who received the second-line treatment of anti-PD-1 single drug (nafulizumab) for the progress of disease after chemotherapy with platinum containing dual drugs
ECoG score is 0, 1 or 2
No serious blood system, heart, lung, liver and kidney dysfunction and immune deficiency
Hemoglobin (HB) 9g / dl; leukocyte (WBC) 3 109 / L; neutrophil (ANC) 1.5 109 / L; platelet (PLT) 75 109 / L
Men or women of childbearing age are willing to take contraceptive measures in the experiment
Estimated survival time 3 months

Exclusion Criteria

Histologically, small cell and non-small cell mixed lung cancer
Pregnant or nursing women
Any unresponsive > CTCAE Level 2 toxicity caused by past anti-tumor treatment
Serum creatinine clearance < 30 ml / min (calculated by Cockcroft Gault formula)
Liver dysfunction, defined as
Serum (total) bilirubin 1.5 upper limit of normal value (ULN)
Serum AST / SGOT or ALT / SGPT > 2.5 ULN (liver metastasis > 5 ULN)
Alkaline phosphatase level > 2.5 ULN (liver metastasis > 5 ULN, or bone) at baseline Transfer patients 10 ULN)
Have a history of uncontrollable or symptomatic angina, arrhythmia or congestive heart failure
Symptomatic brain metastasis or meningeal metastasis
In the past 5 years, she has had or is suffering from other histological types of malignant tumors, except for cervical carcinoma in situ and fully treated skin basal cell carcinoma or squamous cell carcinoma
Have active, or have had and may recur autoimmune diseases. However, subjects with type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia), or no relapse without external triggers are expected
Diagnosis of immunodeficiency or systemic hormone therapy (e.g., hormone therapy equivalent to > 10 mg prednisone per day) or any other form of immunosuppressive therapy within 7 days before the first administration
Patients with known history of human immunodeficiency virus (HIV) infection and / or acquired immunodeficiency syndrome. Subjects with active hepatitis B or active hepatitis C
Grade 2 pneumonia caused by radiotherapy and chemotherapy (grade 2 pneumonia without systemic hormone treatment recovers to grade 1 or below within 14 days, if the researcher judges that there is no risk of recurrence, it can be included in the group for screening)
Have interstitial lung disease and the disease has symptoms
During the study period, radiotherapy is planned for the target focus
Plan to use other anti-tumor therapy during the study period
Patients with serious or uncontrolled systemic diseases who are not suitable for the study or may affect the compliance of the other party's case. Subjects' complications or other conditions may affect compliance with the protocol or may not be suitable for the study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.